SCHEMBL1242311

SCHEMBL1242311

O=C1C(Cl)=C(Nc2cc(F)cc(F)c2)C(=O)c2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.67
▸ HTT P42858 10/20 0.67
▸ RAB9A P51151 9/20 0.67
▸ NPSR1 Q6W5P4 8/20 0.67
▸ KMT2A Q03164 8/20 0.67
▸ MAPK1 P28482 7/20 0.67
▸ NPC1 O15118 6/20 0.67
▸ MEN1 O00255 6/20 0.67
▸ ATM Q13315 5/20 0.67
▸ LMNA P02545 4/20 0.67
▸ GAA P10253 3/20 0.67
▸ MITF O75030 3/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ XBP1 P17861 1/20 0.67
▸ ALDH1A1 P00352 6/20 0.55
▸ CDC25A P30304 5/20 0.55
▸ L3MBTL1 Q9Y468 4/20 0.55
▸ TDP1 Q9NUW8 4/20 0.55
▸ CDC25B P30305 3/20 0.55
▸ HPGD P15428 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8663288 0.85 MAPT (0.74) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL29633261 0.80 MAPT (1.00) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL6506683 0.80 MAPT (1.00) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL1243522 0.80 MAPT (0.73) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL32664539 0.77 MAPT (0.79) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL4873496 0.75 MAPT (1.00) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL7240445 0.75 MAPT (0.74) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL4868219 0.75 MAPT (1.00) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL5808588 0.74 MAPT (0.68) MAPTHTTRAB9ANPSR1KMT2A
SCHEMBL12283300 0.74 MAPT (0.58) MAPTHTTRAB9ANPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 — — US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 — — US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAPT 1551/4885HTT 784/4885RAB9A 1980/4885
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders METAP1, METAP2, ENPEP MAPT 1551/4885HTT 784/4885RAB9A 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback